C07K 14/163
Regulatory proteins
Official title: {Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx}
C07K14/163 (Regulatory proteins) appears on 35 US grants and 51 published applications in this corpus.
Search patents in C07K- Granted patents
- 35
- Published applications
- 51
- Assignees
- 34
- Inventors
- 76
- Latest grant
- 24 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2008 | 0 | 1 |
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 1 | 3 |
| 2012 | 0 | 0 |
| 2013 | 0 | 4 |
| 2014 | 2 | 3 |
| 2015 | 1 | 2 |
| 2016 | 2 | 1 |
| 2017 | 2 | 2 |
| 2018 | 4 | 4 |
| 2019 | 5 | 8 |
| 2020 | 2 | 5 |
| 2021 | 3 | 5 |
| 2022 | 5 | 5 |
| 2023 | 1 | 0 |
| 2024 | 4 | 3 |
| 2025 | 2 | 2 |
| 2026 | 1 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Cell penetrating peptides24 Mar 2026US 12,583,889 B2Oxford University Innovation Limited
- Methods and constructs for production of lentiviral vector19 Aug 2025US 12,391,960 B2Lonza Walkersville, Inc.
- Compositions and methods for treating SARS-CoV-2 infections7 Jan 2025US 12,187,767 B2Morehouse School of Medicine
- HIV/SIV Nef fusion proteins for exosome targeted expression3 Sep 2024US 12,077,564 B2Morehouse School of Medicine
- Methods and constructs for production of lentiviral vector16 Jul 2024US 12,037,599 B2Lonza Walkersville, Inc.
- Cell penetrating peptides2 Jul 2026US 2026/0184743 A1Oxford University Innovation Limited
- Delivery of heterologous proteins26 Feb 2026US 2026/0055146 A1Sana Biotechnology, Inc.
- Artificial protein and uses thereof11 Dec 2025US 2025/0376497 A1Alma Mater Studiorum - Università di Bologna
- Methods and constructs for production of lentiviral vector21 Aug 2025US 2025/0263749 A1Lonza Walkersville, Inc.
- Methods and constructs for production of lentiviral vector10 Oct 2024US 2024/0336936 A1Lonza Walkersville, Inc.
Most cited
By later US patents
- Recombinant HCMV and RHCMV vectors and uses thereof20US 9,249,427 B2Oregon Health & Science University · 2016
- Chloride salt of TAT-NR2B9c14US 10,206,973 B2NoNO Inc. · 2019
- Recombinant HCMV and RHCMV vectors and uses thereof13US 9,982,241 B2Oregon Health & Science University · 2018
- Compositions and methods for treating SARS-CoV-2 infections5US 11,180,534 B1Morehouse School of Medicine · 2021
- Chloride salt of TAT-NR2B9c3US 10,758,589 B2NoNO Inc. · 2020